BRAF and skin squamous cell carcinoma: Furthermore, all these trials demonstrated that BRAF/MEK inhibitors combination seems to modify the toxicity profile of BRAF inhibitors alone, by reducing the incidence of cSCC and other cutaneous proliferative disorders [11, 14].